1,052
Participants
Start Date
November 27, 2015
Primary Completion Date
September 7, 2020
Study Completion Date
December 31, 2027
Apalutamide
Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
Placebo
Participants will receive Placebo orally once daily in each 28 day treatment cycles.
Androgen Deprivation Therapy (ADT)
All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Homewood
Tucson
San Bernardino
San Diego
Denver
Norwalk
Fort Myers
Chicago
Fort Wayne
Jeffersonville
New Orleans
Baltimore
Rockville
Lansing
Troy
Omaha
Las Vegas
Brooklyn
Poughkeepsie
Syracuse
The Bronx
Raleigh
Salisbury
Cleveland
Middleburg Heights
Springfield
Bala-Cynwyd
Bryn Mawr
Lancaster
Charleston
Nashville
Dallas
Houston
San Antonio
Salt Lake City
Richmond
Virginia Beach
Burien
Spokane
Milwaukee
Berazategui
Buenos Aires
C.a.b.a.
Capital Federal
Ciudad Automoma Buenos Aires
Ciudad de Buenos Aires
Córdoba
La Plata
Pergamino
Rosario
San Miguel de Tucumán
San Salvador de Jujuy
Albury
Elizabeth Vale
Kogarah
Port Macquarie
South Brisbane
St Leonards
Barretos
Florianópolis
Goiânia
Ijuí
Natal
Ribeirão Preto
Rio de Janeiro
Salvador
Santo André
São Paulo
Sorocaba
Calgary
Vancouver
Hamilton
Kingston
Toronto
Québec
Beijing
Chengdu
Chongqing
Fuzhou
Guangzhou
Hangzhou
Nanjing
Shanghai
Suzhou
Wuhan
Wuxi
Xi'an
Hradec Králove
Liberec
Nový Jicin
Olomouc
Opava
Pardubice
Prague
Zlín
Clermont-Ferrand
Montpellier
Nancy
Paris
Pierre-Bénite
Strasbourg
Suresnes
Bonn
Braunschweig
Eisleben Lutherstadt
Hamburg
Hanover
Leipzig
Lübeck
Nürtingen
Sindelfingen
Straubing
Budapest
Győr
Pécs
Sopron
Beersheba
Haifa
Holon
Kfar Saba
Petah Tikva
Ramat Gan
Zrifin
Chūōku
Hakata-Ku
Koshigaya
Matsuyama
Minamiku
Miyazaki
Nagano
Nagasaki
Osaka
Osaka Sayama Shi
Sakura
Sapporo
Yokohama
Yufu
Durango
Guadalajara
León
Mexico City
México
Morelia
Zapopan
Bialystok
Bydgoszcz
Krakow
Kutno
Lodz
Lublin
Siedlce
Sochaczew
Warsaw
Wroclaw
Bucharest
Cluj-Napoca
Craiova
Târgu Mureş
Barnaul
Ivanovo
Moscow
Nizhny Novgorod
Obninsk
Omsk
Pyatigorsk
Rostov-on-Don
Ryazan
Saint Petersburg
Saransk
Sochi
Tambov
Tomsk
Tyumen
Ufa
Vologda
Daegu
Daejeon
Goyang-si
Jeollanam-do
Seongnam-si
Seoul
Barcelona
Córdoba
Jerez de la Frontera
Madrid
Pamplona
Gothenburg
Malmo
Örebro
Stockholm
Umeå
Uppsala
Vaxjo
Ankara
Edirne
Istanbul
Izmir
Mersin
Cherkasy
Dnipo
Dnipro
Ivano-Frankivsk
Khakhiv
Kharkiv
Khmelnytsky
Kyiv
Lviv
Odesa
Poltava
Uzhhorod
Vinnitsa
Zaporizhzhya
Carlisle
Dundee
Glasgow
London
Newcastle upon Tyne
Oxford
Plymouth
Scunthorpe
Stockton-on-Tees
Wolverhampton
Lead Sponsor
Aragon Pharmaceuticals, Inc.
INDUSTRY